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During the 1990s, as antimicrobial resistance increased
among pneumococci, many organizations promoted appropri-
ate antimicrobial use to combat resistance. We analyzed data
from the National Ambulatory Medical Care Survey, an annual
sample survey of visits to office-based physicians, and the
National Hospital Ambulatory Medical Care Survey, an annual
sample survey of visits to hospital emergency and outpatient
departments, to describe trends in antimicrobial prescribing
from 1992 to 2000 in the United States. Approximately
1,100–1,900 physicians reported data from 21,000–37,000 vis-
its; 200–300 outpatient departments reported data for
28,000–35,000 visits; ~400 emergency departments reported
data for 21,000–36,000 visits each year. In that period, the pop-
ulation- and visit-based antimicrobial prescribing rates in ambu-
latory care settings decreased by 23% and 25%, respectively,
driven largely by a decrease in prescribing by office-based
physicians. Antimicrobial prescribing rates changed as follows:
amoxicillin and ampicillin, –43%; cephalosporins, –28%; eryth-
romycin, –76%; azithromycin and clarithromycin, +388%;
quinolones, +78%; and amoxicillin/clavulanate, +72%. This
increasing use of azithromycin, clarithromycin, and quinolones
warrants concern as macrolide- and fluoroquinolone-resistant
pneumococci are increasing. 
W
ith the emergence of antimicrobial resistance (1–7), the
use of antimicrobial drugs has increased in both inpatient
(8) and outpatient settings (9,10). From 1995 through 1998, the
overall proportion of isolates of Streptococcus pneumoniae, a
community-acquired pathogen, that were resistant to three or
more antimicrobial drug classes rose substantially (11), and
high rates of antimicrobial use for upper respiratory tract infec-
tions are believed to be a major factor responsible for this
increase. Although the overall antimicrobial prescribing rate by
office-based physicians in the United States did not change
from 1980 through 1992, the rate for children rose by 48% (12),
and in 1992, antimicrobial agents were prescribed second in
frequency behind cardiovascular-renal drugs in physicians’
offices (13). Moreover, in the early 1990s, a sizable proportion
of antibiotic prescriptions provided by office-based physicians
to both children and adults were for colds, upper respiratory
tract infections, and bronchitis, for which these drugs have lit-
tle or no benefit (14,15).
During the 1990s, many organizations (e.g., the Centers for
Disease Control and Prevention [CDC], American Academy of
Pediatrics, American Academy of Family Practice, American
Society of Microbiology, and Alliance for the Prudent Use of
Antibiotics), conducted campaigns to promote appropriate
antimicrobial use (16,17), defined by CDC as use that maxi-
mizes therapeutic impact while minimizing toxicity and the
development of resistance. As a result of these and other efforts
and increased media attention to the problem of antimicrobial
resistance, antimicrobial prescribing for children seen in physi-
cian offices with respiratory infections decreased from 1989
through 2000 (18).
The objective of this study was to describe trends in antimi-
crobial prescribing at visits to office-based physicians, hospital
outpatient departments, and hospital emergency departments in
the United States. The results are based on a secondary data
analysis using the 1992–2000 National Ambulatory Medical
Care Survey (NAMCS) and National Hospital Ambulatory
Medical Care Survey (NHAMCS). 
Methods
Sample Design
NAMCS is a probability sample survey of office-based
physicians in the United States conducted by CDC’s National
Center for Health Statistics. The U.S. Bureau of the Census has
been responsible for field operations and data collection since
NAMCS became an annual survey in 1989. Areport describing
sample design, sampling variance, and estimation procedures
of the NAMCS has been published (19). NAMCS uses a three-
stage probability sampling procedure. The first stage contains
112 geographic primary sampling units. The second stage con-
sists of a probability sample of practicing nonfederally
employed physicians (excluding those in the specialties of
anesthesiology, radiology, and pathology) selected from the
master files maintained by the American Medical Association
and the American Osteopathic Association. Physicians selected
to participate in NAMCS during a particular calendar year are
not eligible to be selected again for at least another 3 years. The
third stage involves selecting patient visits to the sample physi-
cians during a randomly assigned 1-week reporting period in
that year.
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USANHAMCS is an annual probability sample survey of hospi-
tal outpatient departments and emergency departments in the
United States, first conducted in 1992 by CDC’s National
Center for Health Statistics. The U.S. Census Bureau is respon-
sible for field operations and data collection. Apublished report
describes the plan and operation of NHAMCS (20). NHAMCS
uses a four-stage probability sampling procedure. The first-
stage sample contains the same 112 geographic primary sam-
pling units as NAMCS. The second stage consists of a proba-
bility sample of nonfederal, short-stay or general hospitals with
emergency departments, outpatient departments, or both, with-
in the sampled primary sampling units. Hospitals are selected
from a publicly available database of all hospitals in the United
States. The third stage involves selecting emergency service
areas within emergency departments and clinics within outpa-
tient departments. Clinics are classified into six groups: gener-
al medicine, including internal medicine; surgery; pediatrics;
obstetrics/gynecology; substance abuse; and other, which
includes clinics such as psychiatry and neurology. Clinics
where only ancillary services are provided, such as radiology,
physical therapy, and nutrition, are excluded. The fourth stage
consists of sampling patient visits within emergency depart-
ments or clinics during a randomly assigned 4-week reporting
period in that year.
Response Rates and Sample Size
From 1992 through 2000, the response rates ranged from
63% to 73% for NAMCS, 86% to 91% for NHAMCS outpa-
tient departments, and 93% to 97% for NHAMCS emergency
departments. The NAMCS response rate was defined as the
number of eligible physicians who completed the survey plus
the number of eligible physicians who saw no patients during
the study period, divided by the sum of the numerator and the
number of physicians who refused to participate. The NHAM-
CS response rate was defined as the number of completed cases
divided by the sum of the numerator plus the number of case-
patients who refused. For each year of the study, the number of
participating NAMCS physicians ranged from 1,100 to 1,900,
the number of NHAMCS outpatient departments, from 211 to
283, and NHAMCS emergency departments, from 375 to 425.
The number of patient record forms completed each year for
NAMCS ranged from 21,000 to 37,000, for outpatient depart-
ments, from 28,000–35,000, and for emergency departments,
from 21,000–36,000. The number of antimicrobial patient
record forms completed each year for NAMCS ranged from
2,000 to 4,200; for NHAMCS outpatient departments,
2,800–3,500; and for NHAMCS emergency departments,
3,700–6,600.
Data Collection and Coding
The same patient record form is used for both the physi-
cian’s office and outpatient department settings, whereas the
emergency department form differs slightly to reflect the
uniqueness of that setting. The form contains information about
the visit, such as patient’s date of birth and medications pre-
scribed. Physician specialty was recorded for NAMCS during
a personal interview with the physician. Physicians and hospi-
tal staff were instructed to record all new or continued medica-
tions ordered, supplied, or administered at the visit, including
prescription and nonprescription preparations, immunizations,
desensitizing agents, and anesthetics. From 1989 through 1994,
up to five medications were recorded per visit, and from 1995
through 2000, up to six medications were listed per visit. Drugs
were coded according to a classification system developed at
the National Center for Health Statistics. A report describing
the method and instruments used to collect and process drug
information has been published (21). For this analysis, five
drugs were assessed per visit. Since data on the route of admin-
istration were not collected, an attempt was made to delete top-
ical preparations by reviewing trade names and excluding those
intended for topical use (22–25). For this article, antimicrobial
drugs were defined as drugs belonging to the following groups:
quinolones (including nalidixic acid); azithromycin and clar-
ithromycin; erythromycin; amoxicillin and ampicillin; amoxi-
cillin/clavulanate; other penicillins; cephalosporins; trimetho-
prim-sulfamethoxazole; and tetracyclines.
Rate Definitions
Two types of antimicrobial drug use rates were used in the
analysis. The population-based rate was defined as the annual
number of antimicrobial drugs recorded in the three ambulato-
ry care settings divided by the civilian noninstitutional popula-
tion of the United States. The population-based rate accounts
for any changes that may have resulted in a patient being less
likely to have visited an ambulatory care setting (e.g., an
increase in telephone advice, education from a healthcare
provider, or changes in insurance status). The visit-based rate
was defined as the annual number of antimicrobial drugs
recorded in the three ambulatory care settings divided by the
annual number of ambulatory care visits in the United States.
The visit-based rate reflects changes in prescribing behavior
once a visit has occurred.
Statistical Analysis
Data from NAMCS and NHAMCS samples were weighted
to produce national estimates. From 1992 through 1994,
NAMCS weight included three components: selection proba-
bility, nonresponse adjustment, and physician-population
weighting ratio adjustment. In 1995, a fourth component,
weight smoothing, was added. NHAMCS weight includes
three components: selection probability, nonresponse adjust-
ment, and ratio adjustment to fixed totals. SUDAAN statistical
software was used for all statistical analyses (26). The stan-
dard errors used to calculate the 95% confidence intervals (CI)
around the estimates took into account the complex sample
designs of  NAMCS and NHAMCS. All estimates in this
analysis had <30% relative standard error (i.e., the standard
error divided by the estimate expressed as a percentage of the
estimate) and were based on 30 cases or more in the sample
data. Significance of trends was based on a weighted least-
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Results
From 1992 through 2000, the number of antimicrobial drug
prescriptions in ambulatory care settings in the United States
declined from 151 million (95% CI 132 to 169) to 126 million
(95% CI 112 to 141), while the number of visits rose from 908
million (95% CI 842 to 975) to 1.0 billion (95% CI 0.9 to 1.1).
The annual population-based rate of antimicrobial drug use
decreased by 23% (from 599 [95% CI 524 to 673] antimicro-
bial drug prescriptions per 1,000 persons to 461 [95% CI 409
to 513]) (p<0.001), and the annual visit-based rate of antimi-
crobial drug use declined by 25% (from 166 [95% CI 152 to
179] antimicrobial drug prescriptions per 1,000 visits to 125
[95% CI 116 to 133]) (p<0.001) during the study period (Figure
1). All subsequent rates shown are visit-based rates. The
antimicrobial prescribing rate at ambulatory care visits
decreased in persons <15 years of age (–32%; p<0.001), 15–24
years (–9%; p=0.007), and 25–44 years of age (–17%;
p<0.001). No trend was found among persons >45 years
(p=0.03) (Figure 2). For children <15 years of age, antimicro-
bial prescribing rates decreased by 34% in physicians’ offices
(p<0.001) and by 13% in emergency departments (p<0.001),
but no trend was observed in the prescribing rates in outpatient
departments (p=0.17) (Figure 3). The physician’s office was
the only ambulatory care setting which experienced a decline in
antimicrobial prescribing rates for persons >15 years (–24%;
p<0.001), while an increasing trend was seen in outpatient
departments (+35%; p=0.002), and no change was observed in
emergency departments (Figure 4). For visits to physician
offices, antimicrobial prescribing rates decreased for general
and orthopedic surgeons (–45%; p<0.001), general and family
practitioners (–34%; p<0.001), pediatricians (–33%; p<0.001),
and dermatologists (–4%; p=0.006) (Table 1).
During the study period, the antimicrobial prescribing rate
at all ambulatory care visits declined for amoxicillin and ampi-
cillin (–43%;p<0.001), cephalosporins (–28%; p<0.001), and
erythromycin (–76%; p<0.001) (Figure 5); the prescribing rate
rose for azithromycin and clarithromycin (+388%; p<0.001),
quinolones among persons >15 years (+78%; p<0.001), and
amoxicillin/clavulanate among children <15 years (+69%;
p<0.001) (Figure 6). Decreasing trends were also found for
other penicillins (p<0.001), tetracyclines (p<0.001), and
trimethoprim-sulfamethoxazole (p=0.009) (data not shown).
Table 2 shows the rank order of the nine drug classes examined
in 1992 compared with their order in 2000.
Discussion
Our study found decreasing trends in both the population-
and visit-based antimicrobial prescribing rates in ambulatory
care settings from 1992 through 2000. The population-based
prescribing rate provides the number of antimicrobial drugs
used per person in the United States; we used this rate to assess
changes over time that may be attributed to variations in visit-
ing an ambulatory care setting. Declining population-based
antimicrobial prescribing rates may be a result of several fac-
tors: a decrease in visits which, for example, may be due to a
decrease in the incidence of a disease or changes in the patient’s
health insurance coverage; a decrease in prescribing, which
may be the result of an increased understanding by the patient
and/or healthcare provider of the impact of antimicrobial use,
or both. Declining visit-based antimicrobial prescribing rates
only reflect a change in prescribing behavior occurring at
ambulatory care visits.
The decreasing trends in the antimicrobial prescribing rate
found in this study for both children and adults seen in physi-
cians’offices from 1992 through 2000 contrast with findings of
a previous report that examined NAMCS data from 1980
through 1992. That report showed an increasing trend in
antimicrobial prescribing for children and no trends for the
older age groups (12). Although NAMCS data for children
have been published previously in a slightly different format
(18), showing the prescribing rates in all three settings is
important to understanding practice patterns in ambulatory
care. The findings suggest that efforts to promote appropriate
antimicrobial use in physicians’ offices may be effective. 
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Figure 1. Trends in annual antimicrobial prescribing rates—United
States, 1992–2000. Note: all trends shown are significant (p<0.001).
Figure 2. Trends in annual antimicrobial prescribing rates by age—
United States, 1992–2000. Note: trend for visits by patients <15 years
of age, p<0.001; for visits by patients 15–24 years, p=0.007; for visits
by patients 25–44 years, p<0.001.Increasing rates of use were observed for some of the new,
more expensive, broad-spectrum antimicrobial agents, such as
azithromycin and clarithromycin, quinolones, and amoxi-
cillin/clavulanate. The large increase in the use of azithromycin
and clarithromycin may be partially explained by the fact that
clarithromycin was first mentioned in NAMCS and NHAMCS
in 1992 and azithromycin in 1993. While these agents have
been recommended for use in some patients with community-
acquired pneumonia (28), cases of pneumonia are unlikely to
account for this dramatic increase in their use.
Fluoroquinolones and newer macrolides (azithromycin and
clarithromycin) are rarely indicated as first-line therapy for
other respiratory infections (29,30). The decrease in the use of
amoxicillin and ampicillin could be a consequence of the 46%
decrease in visits to physician offices for otitis media from
1989 through 2000 (18).
Antimicrobial use, whether appropriate or inappropriate,
promotes antimicrobial resistance. The increasing use of
azithromycin, clarithromycin, and fluoroquinolones warrants
concern in light of the importance of these agents in the treat-
ment of patients hospitalized with pneumonia, and the rise in
macrolide- and fluoroquinolone-resistant pneumococci in
many parts of the world (11,31–35). Making certain that the
increasing use of these agents is clinically appropriate is impor-
tant. While most efforts to date promoting appropriate antibiot-
ic use have focused on reducing the use of antimicrobial agents
for viral infections, future efforts should be directed towards
ensuring that when antimicrobial agents are indicated, first-line
or targeted therapy is employed.
Decreasing trends in antimicrobial drug prescribing rates
were found for office visits to pediatricians, general and fami-
ly practitioners, dermatologists, and general and orthopedic
surgeons. Interventions may need to be tailored differently to
different settings (e.g., physician’s office versus outpatient
department versus emergency department) and physician spe-
cialty groups. In 2000, the American College of Physicians-
American Society of Internal Medicine (ACP-ASIM) designat-
ed antimicrobial resistance as a focus for their continuing med-
ical education conferences. The ACP-ASIM, together with
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Figure 3. Trends in annual antimicrobial prescribing rates for persons
<15 years of age by setting—United States, 1992–2000. Note: trend for
office setting and emergency departments, p<0.001.
Table 1. Trends in annual antimicrobial drug prescribing rates at physicians’ offices by specialty—United States, 1992–2000 
No. of antimicrobial drug prescriptions/1,000 visits
a 
Physician specialty  1992  1993  1994  1995  1996  1997  1998  1999  2000 
% change 
since 1992 
Pediatrics  353  
(310, 397) 
325 
(276,374) 
302 
(255,349) 
344 
(304,384) 
340 
(291,389) 
299 
(262,336) 
218 
(182,253) 
258 
(202,314) 
235 
(208,263) 
–33
b 
General/family 
practice 
265 
(232,298) 
226 
(199,254) 
241 
(216,267) 
231 
(204,258) 
201 
(178,225) 
207 
(181,234) 
187 
(164,209) 
188 
(160,216) 
176 
(148,204) 
–34
b 
Otolaryngology  182 
(141,223) 
218 
(177,259) 
181 
(146,217) 
197 
(153,241) 
179 
(147,210) 
189 
(122,256) 
169 
(135,203) 
162 
(97,227) 
166 
(128,205) 
–8 
Internal medicine  139 
(114,165) 
147 
(117,178) 
143 
(111,174) 
162 
(137,187) 
147 
(114,180) 
123 
(97,149) 
142 
(122,162) 
138 
(104,173) 
116 
(95,136) 
–17 
Dermatology  138 
(110,167) 
149 
(124,173) 
140 
(114,166) 
134 
(107,161) 
116 
(97,136) 
106 
(75,137) 
112 
(83,141) 
92 
(70,114) 
133 
(110,157) 
–4
b 
Urology  118  
(90, 145) 
129 
(100,158) 
144 
(117,172) 
158 
(120,196) 
122 
(85,159) 
153 
(108,199) 
108 
(84,133) 
131 
(89,172) 
148 
(123,172) 
+26 
General/orthopedic 
surgery 
40 
 (26,54) 
39  
(26,51) 
30  
 (18,42) 
30 
(20,40) 
39  
(24,54) 
44 
 (24,64) 
14  
(7,21) 
28   
(12,44) 
22 
 (14,30) 
–45
b 
All others  39  
 (28,49) 
51 
 (34,68) 
40 
 (31,49) 
50  
(32,69) 
39 
 (26,51) 
37 
 (28,47) 
42  
(30,53) 
30 
 (22,38) 
36 
 (27,45) 
–6 
a95% confidence interval. 
bTrend is significant (p<.01). 
Figure 4. Trends in annual antimicrobial prescribing rates for persons
>15 years of age by setting—United States, 1992–2000. Note: trend for
office setting, p<0.001; trend for outpatient departments, p=0.002.CDC and the American Academy of Family Physicians and the
Infectious Diseases Society of America, has published princi-
ples for appropriate prescribing for upper respiratory infections
in adults (29). These principles will form the scientific basis for
new campaigns to improve prescribing by clinicians who treat
adults. Future analyses of NAMCS and NHAMCS data will
show whether these activities result in changes in prescribing
behavior similar to those seen for children. 
The major limitation of our study is that the appropriateness
of an antimicrobial prescription cannot be assessed in most
instances because diagnosis is not linked to a particular drug.
Patient visits in NAMCS or NHAMCS do not include tele-
phone contacts; therefore, we could not determine whether a
shift to telephone prescribing for antimicrobial agents
occurred. However, we could assess whether prescribing had
made a transition from physicians’offices to emergency depart-
ments or outpatient departments. Ashift to other healthcare set-
tings (at least for children <15 years of age) did not appear to
occur because a decreasing trend was also found in emergency
departments in addition to physicians’ offices, and outpatient
departments did not show a trend. However, for adults, antimi-
crobial drug prescribing declined in physicians’ offices,
remained the same in emergency departments, and rose in out-
patient departments, suggesting that a change in setting could
have occurred. 
The dynamics that influence antimicrobial prescribing are
complex. In recent years, physicians have been receiving mes-
sages about the appropriate use of antimicrobial drugs from the
medical literature, the media, health insurance companies, key
opinion leaders, alternative medicine leaders, and patients (36).
These messages appear to have been absorbed to some extent,
as evidenced by the results shown in this article and the decline
in antimicrobial prescribing in children seen in physicians’
offices (18). However, the increasing use of azithromycin, clar-
ithromycin, and quinolones evokes concern and requires addi-
tional study to determine their appropriateness. New efforts
must be made to promote targeted agents as first-line therapy. 
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